Clinical data published in the peer reviewed journal Medical Cannabis and Cannabinoids shows that a transdermal cannabinoid oil significantly reduces pain associated with diabetic peripheral neuropathy (DPN).
The study, conducted at Don Chan Hospital in Thailand, involved 100 participants in a 12-week randomized, double-blind, placebo-controlled trial. Researchers evaluated the effects of a novel THC:CBD:CBN transdermal formulation on pain in the lower extremities caused by DPN.
Participants were randomly assigned to receive either the cannabinoid oil or a placebo. Pain levels were assessed using the Thai version of the Neuropathic Pain Symptom Inventory (NPSI-T). The results showed a marked decrease in pain scores for those using the cannabinoid formulation, dropping from an average of 25.60 to 5.57. In contrast, the placebo group saw only a slight reduction in scores, from 25.24 to 22.85. Pain reduction was statistically significant across all dimensions at weeks 4, 8, and 12.
Safety data revealed that the cannabinoid oil was well-tolerated, with only 10% of participants reporting mild adverse effects, comparable to those in the placebo group.
The researchers concluded that this cannabinoid formulation is both effective and safe, offering a promising new option for managing pain in patients with diabetic neuropathy.
For more information on this study, click here.
